Patients previously exposed to daratumumab can successfully receive teclistamab combined with daratumumab if they have been off anti-CD38 therapy for at least a year. Faculty emphasize that this approach produces durable remissions despite limited representation in early registration trials.
Clinicians can generally assume CD38 expression is maintained on myeloma cells without repeat testing. However, performing a bone marrow biopsy at relapse is critical to confirm BCMA expression and identify emerging resistance mechanisms before choosing BCMA-targeted engagers.
Belantamab mafodotin remains effective following BCMA CAR-T failure because antibody-drug conjugates do not depend on functional T cells for cytotoxicity. Moreover, rising soluble BCMA levels upon disease progression indicate that surface BCMA remains present and re-targetable.
Microcystic keratopathy from belantamab mafodotin involves superficial corneal epithelial changes rather than posterior chamber damage. Lengthening treatment intervals to every 8 to 12 weeks and delaying doses allows vision to recover while maintaining deep, MRD-negative therapeutic responses.
Clinicians must avoid co-administering proton pump inhibitors with the novel CELMoD mezigdomide. When gastrointestinal acid suppression is indicated, treating teams should switch patients to H2 receptor blockers to prevent adverse drug interactions.
Beyond potent cereblon degradation, preclinical data indicate that mezigdomide stimulates T-cell activation and diminishes exhaustion. Reversing T-cell exhaustion offers a vital biological rationale for combining CELMoDs with bispecific antibodies or using them as bridging regimens.
Despite directing therapy toward the same GPRC5D target, the CAR-T agent arlo-cel exhibits a markedly distinct tolerability profile compared to talquetamab. It spares patients the debilitating dysgeusia and dermatologic nail changes, presenting only low rates of cerebellar neurotoxicity.
